About Levitra

Erectile dysfunction belongs to common pathological conditions. In the U.S. national representative studies were carried out in 2001-2002. The abundance of erectile dysfunction (ED) was 22% with minimal variability in different ethnic groups. In this case, as expected, the abundance of ED grew with age. These figures are consistent with the evaluation of this pathology in the urban areas of Europe, where the overall prevalence of ED among men aged 30 to 80 years was 19.2% - from 2.3% in the youngest group to 53.4% in the elderly. According to research Massachusetts Male Aging Study, an annual record of 26 new cases of erectile dysfunction per 1,000 men aged 40-49 years.

In the above studies, coronary artery disease and its risk factors, such as diabetes, smoking, obesity and hyperlipidemia were significantly associated with erectile dysfunction. This supports the concept that dysfunction of the blood vessels, especially atherosclerotic disease and endothelial dysfunction play an important role in the development of ED. Thus, the main treatment for erectile dysfunction have interventions aimed primarily at the vessels.

In addition to symptomatic treatment for long-term improvement in erectile function requires sequential modification of cardiovascular risk factors, including smoking cessation, treatment of diabetes, hypertension and dyslipidemia, as well as regular physical activity and normalization of body weight.

As the pharmacological class of drugs that affect the impaired vascular function, use of phosphodiesterase-5 inhibitors (PDE-5) among from them is Levitra, effective for many forms of erectile dysfunction in a large percentage of patients. In recent years, these drugs have become first-line therapy for ED.

This review is devoted to basic properties, efficacy and safety of PDE-5 inhibitor for oral administration of Levitra, approved by the FDA for the treatment of ED in 2003, also pharmacodynamic characteristics and performance, special attention will be paid to the safety and tolerability, particularly in patients with cardiovascular risk factors or coronary heart disease.